Two drug classes linked to fewer heart failure flare-ups
Heart failure flare-ups had a hazard ratio—a relative risk measure—of 0.69 over one year with added drugs versus standard care alone.
Our read
Interventions- Studied:
- Study in people
- Why it’s aging research:
- It studies an intervention with evidence of extending healthy life.
Editor of record: Boris Djordjevic · AgingResearch.News
Adults with obesity and heart failure with reduced ejection fraction—a condition in which the heart pumps out a reduced share of blood—but without type 2 diabetes were compared in an observational study designed to mimic a randomized trial. Researchers matched 4,258 people who started liraglutide, semaglutide or tirzepatide alongside standard care with 4,258 receiving standard care alone.
Over one year, starting a drug was linked to fewer heart failure flare-ups and lower mortality (hazard ratio 0.33 for death). No statistically significant differences appeared in acute kidney injury (hazard ratio 0.86); digestive symptoms, delayed stomach emptying or bowel blockage (1.16); gallbladder inflammation or gallstones (1.18); or severe low blood sugar (0.64).
Why it matters
For people aging with heart failure, whether these drugs can accompany existing care without worsening the condition is an important question. The authors called for a dedicated large randomized trial.
Caveats
People prescribed these drugs may have differed in health or care in ways that matching could not account for. Reported in a conference abstract, the findings concern adults with obesity and this form of heart failure without type 2 diabetes, not other patient groups.
The paper
SUNY Downstate Health Sciences Univ; Cardiology
AHA Scientific Sessions 2026 Abstract, Nov 2, 2026
Presented at AHA Scientific Sessions 2026, abstract 15855
Comments
Be the first to comment.